Last reviewed · How we verify
Toxogonin
Toxogonin is a Small molecule drug developed by Aya Sabry Mohamed Mohamed. It is currently FDA-approved for Organophosphate poisoning.
Toxogonin is a small molecule used in the treatment of pesticide poisoning. It is administered intravenously, often in combination with lipid emulsion and atropine, as part of a treatment regimen for pesticide toxicity.
At a glance
| Generic name | Toxogonin |
|---|---|
| Sponsor | Aya Sabry Mohamed Mohamed |
| Target | Acetylcholinesterase |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
- Organophosphate poisoning
Common side effects
Key clinical trials
- Assessing The Role Of Intravenous Lipid Emulsion As A Life Saving Therapy In Pesticides Toxicity (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Toxogonin CI brief — competitive landscape report
- Toxogonin updates RSS · CI watch RSS
- Aya Sabry Mohamed Mohamed portfolio CI
Frequently asked questions about Toxogonin
What is Toxogonin?
What is Toxogonin used for?
Who makes Toxogonin?
What development phase is Toxogonin in?
What does Toxogonin target?
Related
- Target: All drugs targeting Acetylcholinesterase
- Manufacturer: Aya Sabry Mohamed Mohamed — full pipeline
- Therapeutic area: All drugs in Other
- Indication: Drugs for Organophosphate poisoning
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing